The aim of this study is to show the hypoallergenicity of a new thickened rice based formula (TRHF) through a double blind placebo controlled food challenge (DBPCFC), as recommended by the American Academy of Pediatrics, in subjects with IgE-mediated CMA and in subjects with non-IgE-mediated CMA.
The study is made of 2 different steps : 1st step is a double blind randomised food challenge where the new formula is compared to a placebo. The second part of the trial consists in an open phase during which all infants will be fed with the study formula.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
72
new rice based thickened formula
formula previously tolerated by the subject - only for the 1st part of the study
CHR Namur
Namur, Belgium
Hôpital Saint Vincent de Paul - GHICL
Lille, France
Hopital Trousseau
Paris, France
University of Naples Federico II
Naples, Italy
hypoallergenicity
the percentage of children tolerating the formula during the double blind placebo controlled food challenge (TRHF 2017 vs. placebo formula).
Time frame: 7 days
Regurgitations
assessed through Vandenplas score ranging from 0 (=less than 2 regurgitation episodes / day) to 6 (=Regurgitation of the complete volume after each feeding)
Time frame: 1, 2, 3, 4, 5 and 6 months
Vomiting
(on a 4 level scale)
Time frame: 1, 2, 3, 4, 5 and 6 months
Abdominal pain
(severity on a 4 level scale)
Time frame: 1, 2, 3, 4, 5 and 6 months
Bloating and gas
(severity on a 4 level scale)
Time frame: 1, 2, 3, 4, 5 and 6 months
Stool consistency
assessed through Bristol Stools Form Scale from Type A ( Separate hard lumps, like nuts (hard to pass)) to Type G (Watery, not solid pieces - entirely liquid )
Time frame: 1, 2, 3, 4, 5 and 6 months
Stool frequency
(number of stool per day or per week)
Time frame: 1, 2, 3, 4, 5 and 6 months
Blood in stools
(presence/absence)
Time frame: 1, 2, 3, 4, 5 and 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Sleeping time over 24h satisfaction
(presence/absence)
Time frame: 1, 2, 3, 4, 5 and 6 months
Unexplained crying
(yes/no)
Time frame: 1, 2, 3, 4, 5 and 6 months
Respiratory symptoms
(severity on a 4 level scale)
Time frame: 1, 2, 3, 4, 5 and 6 months
Urticaria
(presence/absence)
Time frame: 1, 2, 3, 4, 5 and 6 months
Angioedema
(presence/absence)
Time frame: 1, 2, 3, 4, 5 and 6 months
Eczema
severity assessed through SCORAD
Time frame: 1, 2, 3, 4, 5 and 6 months
Weight
expressed in kg and in z scores according to the World Health Organization (WHO) Child Growth Standards
Time frame: 1, 2, 3, 4, 5 and 6 months
Height
expressed in cm and in z scores according to the WHO Child Growth Standards
Time frame: 1, 2, 3, 4, 5 and 6 months
BMI
expressed in value and z scores according to the WHO Child Growth Standards
Time frame: 1, 2, 3, 4, 5 and 6 months
Head circumference
expressed in cm and in z scores according to the WHO Child Growth Standards
Time frame: 1, 2, 3, 4, 5 and 6 months
Number of patients with treatment emergent Adverse Events
Time frame: 1, 2, 3, 4, 5 and 6 months